FDA expert panel endorses idea of removing a component from flu vaccine
The FDA's expert vaccine advisory panel unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as…
The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as possible, pressing the FDA and manufacturers to try to get the work done on an expedited timeline.
While a representative of vaccine manufacturers warned it may not be possible to remove the influenza B/Yamagata component from the flu vaccines that will be made for the Northern Hemisphere’s 2024-25 season, several members of the Vaccines and Related Biological Products Advisory Committee suggested that should be a goal, at least for the U.S. market.
What's Your Reaction?
